BRIEF-Roche Gets EU Approval For Chronic Lymphocytic Leukaemia Treatment [Reuters]
ROCHE HOLDING LTD S/ADR (RHHBY)
NASDAQ:AMEX Investor Relations:
roche.com/investors.htm
Company Research
Source: Reuters
BRIEF-Roche Gets EU Approval For Chronic Lymphocytic Leukaemia Treatment March 12 (Reuters) - Roche Holding AG: * EUROPEAN COMMISSION APPROVES VENCLYXTO PLUS GAZYVARO FOR ADULTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKAEMIA * COMBINATION REGIMEN OFFERS A NEW 12-MONTH, FIXED-DURATION, CHEMOTHERAPY-FREE TREATMENT OPTION FOR ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA * RESULTS OF THE PHASE III CLL14 STUDY ADD TO THE GROWING BODY OF EVIDENCE SUPPORTING THE POTENTIAL OF VENCLYXTO-BASED COMBINATIONS ACROSS MULTIPLE LINES * DATA SHOWED THAT A FIXED DURATION OF TREATMENT WITH VENCLYXTO PLUS GAZYVARO REDUCED THE RISK OF DISEASE PROGRESSION OR DEATH BY 65% COMPARED TO A CURRENT STANDARD-OF-CARE Source text: bit.ly/2wUPnIP Further company coverage: (Berlin Speed Desk)
Show less
Read more
Impact Snapshot
Event Time:
RHHBY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RHHBY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RHHBY alerts
High impacting ROCHE HOLDING LTD S/ADR news events
Weekly update
A roundup of the hottest topics
RHHBY
News
- Atlas of cells offers a milestone leap in understanding of the human body [CNN]CNN
- Nykode Therapeutics And 2 More Penny Stocks Worth Watching [Yahoo! Finance]Yahoo! Finance
- Neuron23 Announces Usage of Roche's Digital Biomarker and Device in Parkinson's Disease Clinical Trial [Yahoo! Finance]Yahoo! Finance
- Roche receives CE Mark for VENTANA FOLR1 (FOLR1-2.1) RxDx Assay as the first IHC-based companion diagnostic to identify ovarian cancer patients eligible for ELAHERE [Yahoo! Finance]Yahoo! Finance
- Flatiron Health announces research to be presented at American Society of Hematology Annual Meeting and Exposition [Yahoo! Finance]Yahoo! Finance